Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Drug-eluting stent Stories

2013-12-06 08:24:10

NATICK, Mass. and PARSIPPANY, N.J., Dec. 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the Boston Scientific Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System. Under the terms of the agreement, The Medicines Company's acute cardiovascular care sales force will collaborate with the Boston Scientific Interventional Cardiology sales force to provide promotional...

2013-11-26 12:27:22

DUBLIN, Ireland, November 26, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/3t6fpx/coronary_stents) has announced the addition of the "Coronary Stents - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015" [http://www.researchandmarkets.com/research/3t6fpx/coronary_stents ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The...

2013-11-25 08:28:08

Advanced Stent Technology to Launch Immediately in the United States NATICK, Mass., Nov. 25, 2013 /PRNewswire/ -- Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES). The technology is available immediately...

2013-11-21 08:24:09

- Notably Lower Rates of Neoatherosclerosis Reported Following MiStent SES® Implantation Versus Other Drug Eluting Stents - DURHAM, N.C., Nov. 21, 2013 /PRNewswire/ -- Micell Technologies, Inc. today announced that The American Journal of Cardiology(®) published results of a comprehensive analysis of optical coherence tomography (OCT) following MiStent SES implantation. Evaluations of vascular healing taken at multiple time points demonstrated excellent vessel healing with a low rate of...

2013-11-12 23:29:31

ResearchMoz.us includes new market research report "China Interventional Cardiovascular Device Industry Report, 2013 - 2015" to its huge collection of research reports. View Full Report with TOC at: http://www.researchmoz.us/china-interventional-cardiovascular-device-industry-report-2013-2015-report.html. Albany, NY (PRWEB) November 12, 2013 ResearchMoz.us include new market research report "China Interventional Cardiovascular Device Industry Report, 2013 - 2015 " to...

2013-11-12 08:35:58

SINGAPORE, Nov. 12, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for the second quarter of its Fiscal Year 2014 (Q2 FY14) and first half ended 30 September 2013 (H1 FY14). Second Quarter Highlights and Recent Developments: -- Growth in total revenue and product revenue both improved compared...

2013-11-01 11:28:50

'Hybrid procedure' combining minimally invasive corornary artery bypass surgery (CABG) with percutaneous coronary intervention is feasible and safe compared with traditional CABG A hybrid approach to treating coronary artery disease that involves a "hybrid procedure" combining a minimally invasive bypass surgery with percutaneous coronary intervention (PCI) was found to be feasible and safe in a clinical trial. This is the first randomized study of the technique. These findings were...

2013-10-31 10:26:48

Results of the Nordic-Baltic Bifurcation IV trial presented at TCT 2013 A new clinical trial shows that a two-stent technique for treatment of bifurcation lesions with a large stenotic side branch was not associated with significant improved outcomes compared to a provisional stenting approach. The findings from the Nordic-Baltic Bifurcation IV study were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular...

2013-10-30 15:34:04

New study compares 2 newer generation drug-eluting stents with biocompatible and biodegradable polymers A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible polymer stents in patients undergoing percutaneous coronary intervention (PCI). The findings of the SORT-OUT VI trial were presented today at the 25th annual...

2013-10-30 08:32:41

Financial credit provided if second stent is required in a CorPath robotic-assisted angioplasty WALTHAM, Mass., Oct. 30, 2013 /PRNewswire/ -- Corindus Vascular Robotics, a leading provider of precision medical robotics, today announced the launch of its CorPath One Stent Program. The goal of the program is to raise awareness of the potential to decrease longitudinal geographic miss (LGM) caused by sub-optimal stent placement, as well as the patient safety and financial benefits...